3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Status
Completed
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Conditions
Arthritis, Rheumatoid
7
Spondylitis, Ankylosing
2
Psoriasis
2
Colitis, Ulcerative
2
Sarcoidosis
1
Plaque Psoriasis
1
Nephrotic Syndrome
1
Nephrosis, Lipoid
1
Mucopolysaccharidosis VI
1
Mucopolysaccharidosis II
1
Mucopolysaccharidosis I
1
Mucopolysaccharidoses
1
Macular dystrophy, corneal type 1
1
Kidney Diseases
1
Inflammation
1
Hidradenitis Suppurativa
1
Glomerulosclerosis, Focal Segmental
1
Dupuytren Contracture
1
Crohn Disease
1
Arthritis, Psoriatic
1
Acne Vulgaris
1
Abscess
1
Interventions
etrolizumab
5
Infliximab
2
Adalimumab
2
golimumab
1
Papillomavirus Vaccines
1
Mesalamine
1
Injections
1
Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18
1
Andrographis paniculata extract
1
ABX464
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Has results
×
Colitis, Ulcerative
×
Adalimumab
×
Clear all
NCT02163759
2021-07-23
HIBISCUS I
Hoffmann-La Roche
Phase 3
Completed
358 enrolled
42 charts
NCT02171429
2021-07-23
HIBISCUS II
Hoffmann-La Roche
Phase 3
Completed
358 enrolled
38 charts